Corcept Therapeutics Incorporated (CORT)

From the record

Corcept Therapeutics Incorporated's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Corcept Therapeutics Incorporated's 10 filed years say what it did: revenue went from $81 million in fiscal 2016 to $761 million in fiscal 2025, up 28.2% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Corcept Therapeutics Incorporated's diluted share count grew about 1.1% a year, and dividends and buybacks returned about 40% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 113 sales (106 under scheduled 10b5-1 plans) and 2 purchases of their own stock on the open market in the year to 2026-11-04, buying about $3 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Corcept Therapeutics Incorporated earned about 15 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 89 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count grew 5.7% over the year (the filed statements).

From the record

Corcept Therapeutics Incorporated's standing among 315 graded names in its industry family: revenue of $761 million in fiscal 2025 ranks in the top 14% by size; a net margin of 13.1% ranks in the top 15%; revenue growth of 23.7% a year over the last 3 filed years ranks in the top 35% (its annual reports).

From the record

Corcept Therapeutics Incorporated's leadership, from its insiders' filings and its current reports: the chief executive on the record is Belanoff, Joseph K (Chief Executive Officer, as filed), filing under that title since 2006-01-19, 20.8 years (top 1% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 6.7 years (top 31%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (top 20%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Corcept Therapeutics Incorporated's room to grow, from the newest filed statements (fiscal 2025): cash of $120 million against no long-term debt tagged leaves 14.4% of its assets as net cash, bottom 32% of its family; cash from operations less capital spending is 18.6% of revenue (top 15%); a gross margin of 98.3% (top 5%); research spending of 33.5% of revenue (bottom 36%) (its annual report).

From the record

Corcept Therapeutics Incorporated's growth drivers, from the filed years to fiscal 2025: revenue grew 23.7% a year over the last three filed years against 28.2% over all 10, slowing (bottom 44% of its family); the newest year grew 12.8% (top 43%); research spending grew 24.8% a year (top 18%); capital spending grew -20.1% a year (bottom 44%) (its annual reports). Corcept Therapeutics Incorporated tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Corcept Therapeutics Incorporated's newest year against its own record: revenue of $761 million in fiscal 2025 came in 13% below the $875 million its prior three years' pace pointed to (bottom 37% of its family); net income of $100 million against a prior three-year average of $116 million (bottom 36%); a net margin of 13.1% against 22.7% before (bottom 30%) (its annual reports).